I-Mab logo
I-Mab IMAB

Quarterly report 2025-Q2
added 03-07-2026

report update icon

I-Mab Total Assets 2011-2026 | IMAB

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.
Main categories of assets
Current assets (used within one year):
  • Cash and cash equivalents
  • Accounts receivable (amounts owed by customers)
  • Inventory of goods, raw materials, and supplies
  • Short-term investments
Non-current assets (used for more than one year):
  • Fixed assets (buildings, machinery, equipment)
  • Intangible assets (brands, patents, software)
  • Long-term investments
  • Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets I-Mab

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - 6.33 B 1.74 B 2.38 B 1.03 B - - - - - -

All numbers in CNY currency

Indicator range from annual reports

Maximum Minimum Average
6.33 B 1.03 B 2.87 B

Quarterly Total Assets I-Mab

2025-Q2 2024-Q4 2023-Q4 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - 2.61 B 4.07 B - 4.99 B - 5.6 B - - - 6.33 B 4.3 B - - 1.74 B - - - 2.38 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in CNY currency

Indicator range from quarterly reporting

Maximum Minimum Average
6.33 B 1.74 B 4 B

Total Assets of other stocks in the Biotechnology industry

Issuer Total Assets Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
2.03 B - 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
16.1 M $ 0.79 -1.15 % $ 4.31 M chinaChina
Acorda Therapeutics Acorda Therapeutics
ACOR
109 M - -24.86 % $ 820 K usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
1.36 B $ 3.49 0.58 % $ 1.04 B canadaCanada
Frequency Therapeutics Frequency Therapeutics
FREQ
114 M - - $ 528 M usaUSA
argenx SE argenx SE
ARGX
6.2 B $ 700.45 -1.19 % $ 25 B niderlandNiderland
AgeX Therapeutics AgeX Therapeutics
AGE
12 M - -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
18.1 B - - $ 40.3 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
41.4 M $ 3.6 1.41 % $ 8.66 B australiaAustralia
Biophytis SA Biophytis SA
BPTS
12 M - -13.47 % $ 169 M franceFrance
Grifols, S.A. Grifols, S.A.
GRFS
21.4 B $ 7.81 -2.01 % $ 6.83 B spainSpain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
778 M - - $ 1.01 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
1.3 B $ 225.98 -1.32 % $ 5 B danmarkDanmark
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
66.7 M - - $ 26.5 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
15.2 M - -1.52 % $ 24.7 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
529 M $ 4.13 -5.06 % $ 105 M schweizSchweiz
Akero Therapeutics Akero Therapeutics
AKRO
826 M - - $ 3.67 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
180 M - - $ 86.2 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
14.8 M - -18.52 % $ 27.3 M britainBritain
Akouos Akouos
AKUS
279 M - 0.23 % $ 488 M usaUSA
Advaxis Advaxis
ADXS
16.6 M - -9.65 % $ 45.9 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
34.8 M - 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
62.2 M - 10.36 % $ 9.8 M usaUSA
BioCardia BioCardia
BCDA
2.99 M $ 1.26 -0.79 % $ 26.7 M usaUSA
AlloVir AlloVir
ALVR
119 M - 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
107 M - - $ 10.1 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
1.51 B - - - russiaRussia
Anika Therapeutics Anika Therapeutics
ANIK
271 M $ 14.2 -0.7 % $ 208 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
10.1 M - -45.71 % $ 1.2 M canadaCanada
Acer Therapeutics Acer Therapeutics
ACER
11.6 M - 2.71 % $ 14 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
396 M - 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
35.1 M - 5.93 % $ 314 M canadaCanada
Athersys Athersys
ATHX
60.2 M - 3.77 % $ 22.4 M usaUSA
BioNTech SE BioNTech SE
BNTX
22 B $ 91.19 1.21 % $ 27.2 B germanyGermany
Aptinyx Aptinyx
APTX
66.7 M - -39.0 % $ 4.57 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
2.67 M - -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
783 M $ 1.44 -1.37 % $ 367 M britainBritain
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
271 M $ 6.68 -4.57 % $ 183 M israelIsrael
Acasti Pharma Acasti Pharma
ACST
72 M - 4.01 % $ 150 M canadaCanada
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
105 M - - $ 521 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
3.11 B $ 7.92 1.67 % $ 1.31 B britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.77 M - - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
124 M $ 2.54 -5.22 % $ 16 M usaUSA
Certara Certara
CERT
1.56 B $ 6.67 1.6 % $ 1.07 B usaUSA
Athira Pharma Athira Pharma
ATHA
58.8 M - - $ 269 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
9.12 M $ 3.6 -4.0 % $ 7.83 B israelIsrael
CureVac N.V. CureVac N.V.
CVAC
1.16 B - - $ 867 M germanyGermany
Aravive Aravive
ARAV
62.2 M - -13.39 % $ 1.45 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
1.83 M - -2.5 % $ 5.88 M usaUSA